Antisten MV 35 mg instructions for use. Antisten: instructions for use, analogues and reviews, prices in Russian pharmacies

Registration number: LSR-008140/10-160810

Trade name of the drug: Antisten MB

International Nonproprietary Name (INN): trimetazidine

Dosage form: extended-release, film-coated tablets.

Compound: for 1 tablet:
Active substance: trimetazidine dihydrochloride - 35 mg;
Excipients (core): hypromellose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.
Excipients (shell): hypromellose, macrogol, red iron oxide, titanium dioxide.

Description: Biconvex, film-coated tablets of creamy pink color. On a cross section, two layers are visible, the inner layer (core) is white or white with a yellowish tint.

Pharmacotherapeutic group: antihypoxic agent
ATX Code S01EB15

PHARMACOLOGICAL PROPERTIES
Pharmacodynamics
Has an antihypoxic effect.
By directly influencing cardiomyocytes and neurons of the brain, the drug optimizes their metabolism and function. The cytoprotective effect is due to an increase in energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased glycolysis and blockade of fatty acid oxidation).
Trimetazidine maintains myocardial contractility and prevents a decrease in the intracellular content of adenosine triphosphoric acid (ATP) and phosphocreatinine. In conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, and normalizes the intracellular content of potassium ions.
Reduces intracellular acidosis and increased phosphate levels caused by myocardial ischemia and reperfusion. Prevents the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of the electrical potential, reduces the release of creatine phosphokinase (CPK) from cells and the severity of ischemic damage to the myocardium.
Trimetazidine reduces the frequency of angina attacks, reduces the need for nitrates, after 2 weeks of use it increases exercise tolerance, and sharp fluctuations in blood pressure (BP) are reduced. Reduces dizziness and tinnitus of ischemic etiology. In case of vascular pathology of the eye, it restores the functional activity of the retina.

Pharmacokinetics
After taking the drug orally, trimetazidine is quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability - 90%. The time to reach maximum concentration in blood plasma is 3-5 hours. A stable state is achieved after 60 hours. The volume of distribution is 4.8 l/kg. Connection with blood plasma proteins -16%. Trimetazidine is excreted from the body mainly by the kidneys (about 60% unchanged). The half-life is about 7 hours, in patients over 65 years of age - about 12 hours. The renal clearance of trimetazidine directly correlates with creatinine clearance (CC), hepatic clearance decreases with age. Easily penetrates histohematic barriers.

Indications for use
Coronary heart disease: prevention of angina attacks (in complex therapy).
Cochleovestibular disorders of ischemic nature, such as dizziness, tinnitus, hearing impairment. Chorioretinal vascular disorders.

Contraindications

• hypersensitivity to any component of the drug;
• renal failure (creatinine clearance less than 15 ml/min);
• severe liver dysfunction;
• age under 18 years (efficacy and safety have not been established).

Directions for use and doses
Inside, during meals.
Antisten MB is prescribed 1 tablet 2 times a day (morning and evening).
The course of treatment is as recommended by a doctor.

Side effect
Frequency: very often - more than 1/10; often - more than 1/100 and less than 1/10; uncommon - more than 1/1000 and less than 1/100; rarely - more than 1/10000 and less than 1/1000; very rarely - less than 1/10000, including individual messages.
From the digestive system: often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting.
From the cardiovascular system: rarely - orthostatic hypotension, “hot flashes” to the facial skin.
From the central nervous system: often - dizziness, headache; very rarely - extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.
From the skin and subcutaneous fat: often - skin rash, itching, urticaria.
Others: often - asthenia.

Overdose
Currently, no cases of drug overdose have been reported.

Interaction with other drugs
No information available.

special instructions
Do not use to relieve angina attacks!
The drug is not indicated for the initial course of treatment of unstable angina or myocardial infarction.
If an attack of angina occurs, treatment should be reviewed and adapted. If you miss one or more doses of the drug, you cannot take a higher dose at the next dose! A"

Impact on the ability to drive vehicles and operate machinery
The drug ANTISTEN MB does not have a significant effect on the ability to drive vehicles and perform other work that requires a high speed of psychomotor reactions.

Release form
Extended-release film-coated tablets 35 mg.
10, 30 tablets are placed in a contour cell packaging made of polyvinyl chloride film and printed varnished aluminum foil.
10, 20, 30, 40, 50, 60 or 100 tablets are placed in a polymer container for medicines. One container or 1,2, 3,4, 5,6 or 10 blister packs along with instructions for use are placed in a cardboard pack.

Storage conditions
List B.
Store in a dry place, protected from light, at a temperature not exceeding 25°C.
Keep out of the reach of children.

Best before date
3 years.
Do not use after expiration date.

Conditions for dispensing from pharmacies
On prescription.

Manufacturer
Ozon LLC
Legal address:
445351, Russia, Zhigulevsk, Samara region, st. Pesochnaya, 11
Address for correspondence (actual address, including for receiving claims):
445351, Russia, Zhigulevsk, Samara region, st. Hydrostroiteley, 6.

In this article you can read the instructions for use of the drug Antisten. Reviews of site visitors - consumers of this medicine, as well as the opinions of specialist doctors on the use of Antisten in their practice are presented. We kindly ask you to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not stated by the manufacturer in the annotation. Analogues of Antisten in the presence of existing structural analogues. Use for the treatment of coronary heart disease and other vascular disorders in adults, children, as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

Antisten- a drug that normalizes the energy metabolism of cells exposed to hypoxia or ischemia. Prevents a decrease in intracellular ATP content, ensures the normal functioning of membrane ion channels, transmembrane transport of potassium and sodium ions and the preservation of cellular homeostasis.

Trimetazidine (the active ingredient of the drug Antisten) slows down the oxidation of fatty acids due to the selective inhibition of long-chain 3-ketoacetyl-CoA thiolase, which leads to increased glucose oxidation and restoration of the coupling between glycolysis and oxidative decarboxylation and has been shown to protect the myocardium from ischemia. The switch from fatty acid oxidation to glucose oxidation underlies the antianginal effect of trimetazidine.

Experimental studies on animals have shown that Antisten supports the energy metabolism of the heart and neurosensory organs during periods of ischemic episodes; reduces the amount of intracellular acidosis and the degree of changes in the transmembrane ion flow that occurs during ischemia; reduces the level of migration and infiltration of polynuclear neutrophils in ischemic and reperfusion tissues of the heart, reduces the size of myocardial damage; however, it does not affect hemodynamics.

Compound

Trimetazidine dihydrochloride + excipients.

Pharmacokinetics

Antisten is quickly and almost completely absorbed by the intestinal mucosa. Bioavailability is 90%. Plasma protein binding is 16%. It is excreted by the kidneys (about 60% unchanged).

Indications

• IHD: prevention of angina attacks (in complex therapy);
• cochleovestibular disorders of ischemic nature, such as dizziness, tinnitus, hearing impairment;
• chorioretinal vascular disorders.

Release forms

Film-coated tablets 20 mg.

Extended-release, film-coated tablets MB 35 mg.

Instructions for use and dosage regimen

Taken orally at a dose of 40-60 mg per day, dosage frequency 2-3 times a day. The duration of therapy is determined individually, depending on the clinical situation.

MB extended-release tablets

Inside, during meals.

Antisten MV is prescribed 1 tablet 2 times a day (morning and evening). The course of treatment is determined by the doctor individually.

Side effect

• allergic reactions (including skin rash, itching);
• extrapyramidal disorders (tremor, rigidity, akinesia);
• dizziness;
• headache;
• asthenia;
• nausea, vomiting;
• diarrhea;
• dyspepsia;
• gastralgia.

Contraindications

• pregnancy;
• lactation period (breastfeeding);
• age under 18 years (efficacy and safety have not been established);
• renal failure (creatinine clearance less than 15 ml/min);
• hypersensitivity to trimetazidine.

Use during pregnancy and breastfeeding

Animal studies have not revealed a teratogenic effect, however, due to the lack of clinical data on the safety of the drug during pregnancy, the risk of fetal malformations cannot be excluded. The use of Antisten during pregnancy is contraindicated.

It is not known whether Antisten is excreted in breast milk. If it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided.

Use in children

Contraindicated in children and adolescents under 18 years of age (efficacy and safety have not been established).

special instructions

Do not use to relieve angina attacks!

The drug is not indicated for the initial course of treatment of unstable angina or myocardial infarction.

If an attack of angina occurs, treatment should be reviewed and adapted.

If you miss one or more doses of the drug, you should not take a higher dose at the next dose.

Impact on the ability to drive vehicles and operate machinery

The drug Antisten does not have a significant effect on the ability to drive vehicles and perform other work that requires a high speed of psychomotor reactions.

Drug interactions

There is no information about drug interactions between the drug.

Analogues of the drug Antisten

Structural analogues of the active substance:

• Angiosil retard;
• Antisten MV;
• Deprenorm MV;
• Carditrim;
• Metaguard;
• Predisin;
• Preductal;
• Preductal MV;
• Precard;
• Rimecore;
• Rimecor MV;
• Triducard;
• Trimectal;
• Trimectal MV;
• Trimet;
• Trimetazide;
• Trimetazidine;
• Trimetazidine MB;
• Trimetazidine dihydrochloride;
• Trimitard MV.

If there are no analogues of the drug for the active substance, you can follow the links below to the diseases for which the corresponding drug helps, and look at the available analogues for the therapeutic effect.

Antisten MV: instructions for use and reviews

Dosage form

Extended-release film-coated tablets

Compound

Special packaging 1+1

Trimetazidine dihydrochloride 35 mg

Excipients: hypromellose - 93 mg, microcrystalline cellulose - 178.9 mg, colloidal silicon dioxide - 1.55 mg, magnesium stearate - 1.55 mg.

Film shell composition: opadry II 85F240012 Pink (polyvinyl alcohol - 4 mg, macrogol 3350 - 2.438 mg, red iron oxide dye - 0.04 mg, yellow iron oxide dye - 0.022 mg, talc - 1.48 mg, titanium dioxide - 2.02 mg).

Pharmacodynamics

Has an antihypoxic effect. By directly influencing cardiomyocytes and neurons of the brain, the drug optimizes their metabolism and function. The cytoprotective effect is due to an increase in energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased glycolysis and blockade of fatty acid oxidation).

Trimetazidine maintains myocardial contractility and prevents a decrease in the intracellular content of ATP and phosphocreatinine. In conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, and normalizes the intracellular content of potassium ions.

Reduces intracellular acidosis and increased phosphate levels caused by myocardial ischemia and reperfusion. Prevents the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of the electrical potential, reduces the release of CK from cells and the severity of ischemic damage to the myocardium.

Trimetazidine reduces the frequency of angina attacks, reduces the need for nitrates, after 2 weeks of use it increases exercise tolerance, and sharp fluctuations in blood pressure are reduced. Reduces dizziness and tinnitus of ischemic etiology. In case of vascular pathology of the eye, it restores the functional activity of the retina.

Pharmacokinetics

Suction and distribution

After taking the drug orally, trimetazidine is quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability - 90%. The time to reach Cmax in blood plasma is 3-5 hours. The equilibrium state is reached after 60 hours. Vd is 4.8 l/kg. Plasma protein binding - 16%. Easily penetrates histohematic barriers.

Removal

Trimetazidine is excreted from the body mainly by the kidneys (about 60% unchanged). T1/2 about 7 hours.

Pharmacokinetics in special clinical situations

T1/2 in patients over 65 years of age is about 12 hours. The renal clearance of trimetazidine directly correlates with CC, hepatic clearance decreases with age.

Side effects

Frequency: very often - more than 1/10; often - more than 1/100 and less than 1/10; uncommon - more than 1/1000 and less than 1/100; rarely - more than 1/10000 and less than 1/1000; very rarely - less than 1/100000, including individual messages.

From the digestive system: often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting.

From the cardiovascular system: rarely - orthostatic hypotension, flushing of the facial skin.

From the side of the central nervous system: often - dizziness, headache; very rarely - extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.

Dermatological reactions: often - skin rash, itching, urticaria.

Other: often - asthenia.

Selling Features

prescription

Special conditions

Do not use to relieve angina attacks!

The drug is not indicated for the initial course of treatment of unstable angina or myocardial infarction.

If an attack of angina occurs, treatment should be reviewed and adapted.

If you miss one or more doses of the drug, you should not take a higher dose at the next dose.

Impact on the ability to drive vehicles and operate machinery

The drug Antisten MV does not have a significant effect on the ability to drive vehicles and perform other work that requires a high speed of psychomotor reactions.

Indications

IHD: prevention of angina attacks (in complex therapy);

Cochleovestibular disorders of ischemic nature, such as dizziness, tinnitus, hearing impairment;

Choreoretinal vascular disorders.

Contraindications

Hypersensitivity to any component of the drug;

Renal failure (creatinine clearance less than 15 ml/min);

Severe liver dysfunction;

Age up to 18 years (efficacy and safety have not been established).

Drug interactions

There is no information about drug interactions between the drug.

Prices for Antisten MV in other cities

C.01.E.B Other drugs for the treatment of heart disease

C.01.E.B.15 Trimetazidine

-Hypersensitivity to any component of the drug;

Renal failure (creatinine clearance less than 15 ml/min);

Severe liver dysfunction;

Age up to 18 years (efficacy and safety have not been established).